focus -WSS

focus

author：explore 2025-09-30 06:20:11 - browse：93527

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Suspects arrested after 3 women attacked on Manhattan's West Side: Police

entertainment

WSS

An outrageous hospital charge: I paid $710 for an hour of babysitting

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Timeline: Special counsel's probe into Trump's handling of classified documents

'The boss' wants server deleted: New allegations emerge in Trump indictment

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

explore

focus

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

Sports medicine is finally prioritizing gender equality

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

What does generative AI mean for health care? We asked experts

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

VC firm RA Capital starts a new synthetic biology incubator

Wildfire smoke exposes gaps in outdoor worker protections

CDC: Cases of alpha

leisure time

Pfizer's RSV vaccine recommended for approval in Europe

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

A new deal aims to ramp up use of AI in rehab care decisions

What is artificial intelligence? Experts weigh in

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

focus

leisure time

entertainment

knowledge